36052-27-4

Basic information

• Product Name: 3-Aminopyridine-2-carboxylic acid methyl ester
• Synonyms: 3-Aminopyridine-2-carboxylic acid methyl ester;2-Pyridinecarboxylicacid,3-amino-,methylester(9CI);methyl 3-aminopyridine-2-carboxylate;Methyl 3-aminopicolinate;2-Pyridinecarboxylic acid, 3-aMino-, Methyl ester;Methyl 3-amino-2-pyridine carboxylate
• CAS NO: 36052-27-4
• Molecular Formula: C₇H₈N₂O₂
• Molecular Weight: 152.15062
• Product Categories: GLYCINESCAFFOLD;Esters;Pyridines;Heterocycle-Pyridine series
• Mol File: 36052-27-4.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 317.293 °C at 760 mmHg
• Flash Point: 145.694 °C
• Appearance: /
• Density: 1.239 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.65±0.10(Predicted)
• CAS DataBase Reference: 3-Aminopyridine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Aminopyridine-2-carboxylic acid methyl ester(36052-27-4)
• EPA Substance Registry System: 3-Aminopyridine-2-carboxylic acid methyl ester(36052-27-4)

Safety Data

• Hazardous Substances Data: 36052-27-4(Hazardous Substances Data)

Usage

Uses

3-Aminopyridine-2-carboxylic acid methyl ester can be used as organic synthesis intermediates and pharmaceutical intermediates, mainly used in laboratory research and development processes and chemical production processes.

Synthesis

To a solution of 3-aminopyridine-2-carboxylic acid (20 g, 144.9 mmol) in methanol (300 mL) was added conc. sulfuric acid (5.4 mL), and the mixture was heated under reflux for 5 days. The reaction mixture was concentrated under reduced pressure, water was added thereto, and sodium carbonate was added thereto until the complete of foaming. The mixture was extracted with dichloromethane (x3), the organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give methyl 3-aminopyridine-2-carboxylate (17.0 g, 77%) as a pale yellow solid. 1H-NMR(300MHz,CDCl3):δ3.95(3H,s),5.72(2H,brs),7.03(1H,dd,J=0.99,8. 35Hz),7.18-7.21(1H,m),8.05(1H,dd,J=0.96,4.04Hz).

InChI:InChI=1/C7H8N2O2/c1-11-7(10)6-5(8)3-2-4-9-6/h2-4H,8H2,1H3

Upstream product

• 912369-42-7 methyl 3-{[(tert-butoxy)carbonyl]amino}pyridine-2-carboxylate 
• 186581-53-3 diazomethane 
• 1462-86-8 3-amino-pyridine-2-carboxylic acid 
• 67-56-1 methanol 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 4664-00-0 2,3-pyridinedicarboximide 

Downstream Products

• 400722-89-6 methyl 3-benzoylaminopicolinate 
• 400722-90-9 methyl 3-p-nitrobenzoylaminopicolinate 
• 181123-14-8 methyl 3-amido-(N-phenylacetyl)picolinate 
• 107468-56-4 methyl 3-((methoxycarbonyl)amino)picolinate 
• 824429-51-8 N-[2-(hydroxymethyl)pyridin-3-yl]carbamic acid tert-butyl ester 
• 28252-82-6 2,4-dichloro-1,5-naphthyridine 
• 60058-16-4 1,5-naphthyridine-2,4-diol 

Relevant articles and documents

PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS

The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).

Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii

Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the first step in the glycolysis pathway, along with a larger collection of new structural derivatives. The focused screen of 22 compounds showed a 77% hit rate (>50% multistage inhibition) and revealed a series of aminobenzamide-linked picolinic acids with submicromolar potency against both T. gondii parasite forms. Picolinic acid 23, designed from an antiparasitic benzamidobenzoic acid class with challenging ADME properties, showed 60-fold-enhanced solubility, a moderate LogD7.4, and a 30% improvement in microsomal stability. Furthermore, isotopically labeled glucose tracing revealed that picolinic acid 23 does not function by hexokinase inhibition. Thus, we report a new probe scaffold to interrogate dual-stage inhibition of T. gondii.

HETEROCYCLIC COMPOUND

The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.